Animal models for growth hormone gene therapy

Current Gene Therapy

Volumn 5, Issue 5, 2005, Pages 493-509

  Peroni, Cibele N ^a   Gout, Peter W ^b   Bartolini, Paolo ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Adenoviral vector; Encapsulated cells; Endothelial cells; Fibroblast; Keratinocyte; Mesothelial cells; Myoblast; Naked DNA

Indexed keywords

ALPHA ACTIN; BETA ACTIN; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; ELONGATION FACTOR 1ALPHA; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; MIFEPRISTONE; NAKED DNA; PLASMID DNA; POLITEF; POVIDONE; RAPAMYCIN; THYMIDINE KINASE; TRANSCRIPTION FACTOR; UBIQUITIN C;

CELL ENCAPSULATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG PURIFICATION; EX VIVO STUDY; GENE TRANSFER; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEMOPHILIA B; HORMONAL THERAPY; HUMAN; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN DEFICIENCY; RECOMBINANT DNA TECHNOLOGY; REVIEW; SECOND CANCER; SOMATIC GENE THERAPY; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; DOGS; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; GROWTH HORMONE; MICE; MODELS, ANIMAL; PLASMIDS; RATS;

ANIMALIA;

EID: 26844545020     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774329258     Document Type: Review

References (132)

1. Aiuti, A., Vai, S., Mortellaro, A., Casorati, G., Ficara, F., Andolfi, G., Ferrari, G., Tabucchi, A., Carlucci, F., Ochs, H.D., Notarangelo, L.D., Roncarolo, M.G., and Bordignon, C. (2002a) Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat. Med., 8: 423-425.
2. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., and Bordignon, C. (2002b) Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296: 2410-2413.
3. Al-Hendy, A., Hortelano, G., Tannenbaum, G.S., and Chang, P.L. (1995) Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts - an alternate approach to somatic gene therapy. Hum. Gene Ther., 6: 165-175.
4. Al-Hendy, A., Hortelano, G., Tannenbaum, G.S., and Chang, P.L. (1996) Growth retardation - an unexpected outcome from growth hormone gene therapy in normal mice with microencapsulated myoblasts. Hum. Gene Ther., 7: 61-70.
5. Amalfitano, A. (2003) Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities. Curr. Opin. Mol. Ther., 5: 362-366.
6. Anderson, W.F. (1984) Prospects for human gene therapy. Science, 226: 401-409.
7. Anderson, W.F. (1992) Human gene therapy. Science, 256: 808-813.
8. Anderson, W.F. (2002) The current status of clinical gene therapy. Hum. Gene Ther., 13: 1261-1262.
9. Anwer, K., Shi, M., French, M.F., Muller, S.R., Chen, W., Liu, Q.S., Proctor, B.L., Wang, J.J., Mumper, R.J., Singhal, A., Rolland, A.P., and Alila, H.W. (1998) Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. Hum. Gene Ther., 9: 659-670.
10. Barrandon, Y., Li, V., and Green, H. (1988) New techniques for the grafting of cultured human epidermal cells onto athymic animals. J. Invest. Dermatol., 91: 315-318.
11. Barr, E., and Leiden, J.M. (1991) Systemic delivery of recombinant proteins by genetically modified myoblasts. Science, 254: 1507-1509.
12. Barsoum, S.C., Milgram, W., Mackay, W., Cobletz, C., Delaney, K.H., Kwiecien, J.M., Kruth, S.A., and Chang, P.L. (2003) Delivery of recombinant gene product to canine brain with the use of microencapsulation. J. Lab. Clin. Med., 142: 399-413.
13. Bell, E., Ivarsson, B., and Merrill, C. (1979) Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc. Natl. Acad. Sci. USA, 76: 1274-1278.
14. Bellini, M.H., and Bartolini, P. (1993) In vivo bioassay for the potency determination of human growth hormone in dwarf "little" mice. Endocrinology, 132: 2051-2055.
15. Bellini, M.H., Mathor, M.B., De Luca, M., Cancedda, R, and Bartolini, P. (1998). Ultrasensitive in vivo bioassay detects bioactive human growth hormone in transduced primary human keratinocytes. J. Endocrinol. Invest., 21: 1-6.
16. Bellini, M.H., Peroni, C.N., and Bartolini P. (2003) Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes. FASEB J., 17: 2322-2324.
17. Bickenbach, J.R. (2003) The continuing saga of epidermal stem cells. J. Invest. Dermatol., 121: XV-XVI.
18. -) SCID - initial trials results after 4 years. Science, 270: 475-480.
19. Blau, H.M., and Springer, M.L. (1995) Gene therapy - a novel form of drug delivery. N. Engl. J. Med., 333: 1204-1207.
20. Burcin, M.M., Schiedner, G., Kochanek, S., Tsai, S.Y., and O'Malley, B.W. (1999) Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA, 96: 355-360.
21. Bustin, S.A., and Jenkins, P.J. (2001) The growth hormone-insulin-like factor-I axis and colorectal cancer. Trends Mol. Med., 7: 447-454.
22. Buz'Zard, A.R., Peng, Q.L., and Lau, B.H.S. (2002) Kyolic® and Pycnogenol® increase human growth hormone secretion in genetically-engineered keratinocytes. Growth Horm. IGF Res., 12: 34-40.
23. Cao, T.Y., Tsai, S.Y., O'Malley, B.W., Wang, X.J., and Roop, D.R. (2002) The epidermis as a bioreactor: topically regulated cutaneous delivery into the circulation. Hum. Gene Ther., 13: 1075-1080.
24. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.L., Bousso, P., Le Deist, F., and Fischer, A. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288: 669-672.
25. Cavazzana-Calvo, M., Thrasher, A., and Mavilio, F. (2004) The future of gene therapy. Nature, 427: 779-781.
26. Chang, P.L., Shen, N., and Westcott, A.J. (1993) Delivery of recombinant gene products with microencapsulated cells in vivo. Hum. Gene Ther., 4: 433-440.
27. Chang, P.L., Hortelano, G., Tse, M., and Awrey, D.E. (1994) Growth of recombinant fibroblasts in alginate microcapsules. Biotechnol. Bioeng., 43: 925-933.
28. Chang, P.L., and Bowie, K.M. (1998) Development of engineered cells for implantation in gene therapy. Adv. Drug Deliv. Rev., 33: 31-43.
29. Chen, B.F., Chang, W.C., Chen, S.T., Chen, D.S., and Hwang, L.H. (1995) Long-term expression of the biologically active growth hormone in genetically modified fibroblasts after implantation into a hypophysectomized rat. Hum. Gene Ther., 6: 917-926.
30. Cheng, W.T.K., Chen, B.C., Chiou, S.T., and Chen, C.M. (1998) Use of nonautologous microencapsulated fibroblasts in growth hormone gene therapy to improve growth of midget swine. Hum. Gene Ther.; 9: 1995-2003.
31. Chen, N.Y., Chen, W.Y., Striker, L.J., and Kopchick, J.J. (1997) Coexpression of bovine growth hormone (GH) and human GH antagonist genes in transgenic mice. Endocrinology, 138: 851-854.
32. Choate, K.A., and Khavari P.A. (1997) Sustainability of keratinocyte gene transfer and cell survival in vivo. Hum. Gene Ther., 8: 895-901.
33. Christensen, R., Jensen, U.B., and Jensen, T.G. (2001) Cutaneous gene therapy - an update. Histochem. Cell Biol., 115: 73-82.
34. Chuah, M.K.L., Collen, D., and VandenDriessche, T. (2004) Clinical gene transfer studies for hemophilia A. Semin.Thromb. Hemost., 30: 249-256.
35. Coleman, M.E., De Mayo, F., Yin, K.C., Lee, H.M., Geske, R., Montgomery, C., and Schwartz, R.J. (1995) Myogenic vector expression of insulin-like growth factor-I stimulates muscle cell differentiation and myo-fiber hypertrophy in transgenic mice. J. Biol. Chem., 270: 12109-12116.
36. Dagnaes-Hansen, F., Holst, H.U., Sondergaard, M., Vorup-Jensen, T., Flyvbjerg, A., Jensen, U.B., and Jensen, T.G. (2002) Physiological effects of human growth hormone produced after hydrodynamic gene transfer of a plasmid vector containing the human ubiquitin promotor. J. Mol. Med., 80: 665-670.
37. Dellambra, E., Vailly, J., Pellegrini, G., Bondanza, S., Golisano, O., Macchia C., Zambruno, G., Meneguzzi, G., and De Luca, M. (1998) Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum. Gene Ther.; 9: 1359-1370.
38. Dellambra, E., Pellegrini, G., Guerra, L., Ferrari, G., Zambruno, G., Mavilio, F., and De Luca, M. (2000) Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa. Hum. Gene Ther., 11: 2283-2287.
39. De Luca, M., Albanese, E., Bondanza, S., Megna, M., Ugozzoli, L., Molina, F., Cancedda, R., Santi, P.L., Bormioli, M., Stella, M., and Magliacani, G. (1989) Multicentre experience in the treatment of burns with autologous and allogenic cultured epithelium, fresh or preserved in a frozen state. Burns, 15: 303-309.
40. Dhawan, J., Pan, L.C., Pavlath, G.K., Travis, M.A., Lanctot, A.M., and Blau, H.M. (1991) Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science, 254: 1509-1512.
41. Doehmer, J., Barinaga, M., Vale, W., Rosenfeld, M.G., Verma, I.M., and Evans, R.M. (1982) Introduction of rat growth hormone gene into mouse fibroblasts via a retroviral DNA vector: expression and regulation. Proc. Natl. Acad. Sci. USA, 79: 2268-2272.
42. Draghia-Akli, R., Li, X.G., and Schwartz, R.J. (1997) Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector. Nat. Biotechnol., 15: 1285-1289.
43. Draghia-Akli, R., Hahn, K.A., King, G.K., Cummings, K.K., and Carpenter R.H. (2002a) Effects of plasmid-mediated growth hormone-releasing hormone in severely debilitated dogs with cancer. Mol. Ther., 6: 830-836.
44. Draghia-Akli, R., Malone, P.B., Hill, L.A., Ellis, K.M., Schwartz, R.J., and Nordstrom, J.L. (2002b) Enhanced animal growth via ligand-regulated GHRH myogenic-injectable vectors. FASEB J., 16: 426-428.
45. Dunnwald, M., Tomaneck-Chalkley, A., Alexandrunas, D.,, Fishbaugh, J., and Bickenbach, J.R. (2001) Isolating a pure population of epidermal stem cells for use in tissue engineering. Exp. Dermatol., 10: 45-54.
46. Edelstein, M.L., Abedi, M.R., Wixon, J., and Edelstein, R.M. (2004) Gene therapy clinical trials worldwide 1989-2004 - an overview. J. Gene Med., 6: 597-602.
47. Fan, M.Y., Lum, Z.P., Fu, X.W., Levesque, L., Tai, I.T., and Sun, A.M. (1990) Reversal of diabetes in BB-rats by transplantation of encapsulated pancreatic islets. Diabetes, 39: 519-522.
48. Fenjves, E.S., Smith, J., Zaradic, S., and Taichman, L.B. (1994) Systemic delivery of secreted protein by grafts of epidermal keratinocytes: prospects for keratinocyte gene therapy. Hum. Gene Ther., 5: 1241-1248.
49. Friedmann, T. (1989) Progress toward human gene therapy. Science, 244: 1275-1281.
50. Furstenberger, G., and Senn, H.J. (2002) Insulin-like growth factors and cancer. Lancet Oncol., 3: 298-302.
51. Garlick, J.A., and Taichman, L.B. (1994) Effect of TGF-β1 on reepithelization of human keratinocytes in vitro: an organotypic model. J. Invest. Dermatol., 103: 554-559.
52. Gerrard, A.J., Hudson, D.L., Brownlee, G.G., and Watt, F.M. (1993) Towards gene therapy for haemophilia B using primary human keratinocytes. Nature Genet., 3, 180-183.
53. Ghazizadeh, S., Kalish, R.S., and Taichman, L.B. (2003) Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol. Ther., 7: 296-303,
54. Ghazizadeh, S., and Taichman, L.B. (2005) Organization of stem cells and their progeny in human epidermis. J. Invest. Dermatol., 124: 367-372.
55. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M., and Fisher, A. (2003a) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348: 255-256.
56. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fisher, A., and Cavazzana-Calvo, M. (2003b) LM02-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302: 415-419.
57. Hahn, T.M., Copeland, K.C., and Woo, S.L.C. (1996) Phenotypic correction of dwarfism by constitutive expression of growth hormone. Endocrinology, 137: 4988-4993.
58. Hardy, C.L., Bhatal, P.S., Snibson, K.J., and Adams, T.E. (1997) Comparison of intrahepatic lymphocytes from normal and growth hormone transgenic mice with chronic hepatitis and liver cancer. Immunology., 90: 412-420.
59. He, X., Goldsmith, C.M., Marmary, Y., Wellner, R.B., Parlow, A.F., Nieman, L.K., and Baum, B.J. (1998) Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. Gene Ther., 5: 537-541.
60. Heartlein, M.W., Roman, V.A., Jiang, J., Sellers, J.W., Zuliani, A.M., Treco, D.A., and Selden, R.F. (1994) Long-term production and delivery of human growth hormone in vivo. Proc. Assoc. Am. Physicians, 91: 10967-10971.
61. Hengge, U.R. (2005) Progress and prospects of skin gene therapy: a ten year history. Clin. Dermatol., 23: 107-114.
62. Hoff, C.M., Cusick, J.L., Masse, E.M., Jackman, R.W., Nagy, J.A., and Shockley, T.R. (1998) Modulation of transgene expression in mesothelial cells by activation of an inducible promoter. Nephrol. Dial. Transplant., 13: 1420-1429.
63. Huard, J., Acsadi, G., Jani, A., Massie, B., and Karpati, G. (1995) Gene transfer into skeletal muscles by isogenic myoblasts. Hum. Gene Ther., 5: 949-958.
64. Jensen, U.B., Jensen, T.G., Jensen, P.K.A., Rygaard, J., Hansen, B.S., Fogh, J., Kolvraa, S., and Bolund, L. (1994) Gene transfer into culture human epidermis and its transplantation onto immunodeficient mice: an experimental model for somatic gene therapy. J. Invest. Dermatol., 103: 391-394.
65. Josephs, S.F., Loudovaris, T., Dixit, A., Young, S.K., and Johnson, R.C. (1999) In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices. J. Mol. Med., 77: 211-214.
66. Kay, M.A., Liu, D., and Hoogerbrugge, P.M. (1997) Gene therapy. Proc. Natl. Acad. Sci. USA, 94: 12744-12746.
67. Khandwala, H.M., McCutcheon, I.E., Flyvbjerg, A., and Friend, K.E. (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 21: 215-244.
68. Kolodka, T.M., Garlick, J.A., and Taichman, L.B. (1998) Evidence for keratinocyte stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced keratinocytes. Proc. Natl. Acad. Sci. USA, 95: 4356-4361.
69. Krajcik, R.A., Borofsky, N.D., Massardo, S., and Orentreich, N. (2002) Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol. Biomarkers Prev., 11: 1566-1573.
70. Krueger, G.G., Jorgensen, C.M., Matsunami, N., Morgan, J.R., Liimata, A., Meloni-Ehrig, A., Shepard, R., and Petersen, M.J. (1999) Persistent transgene expression and normal differentiation of immortalized human keratinocytes in vivo. J. Invest. Dermatol., 112: 233-239.
71. Lanzi, R., and Tannenbaum, G.S. (1992) Time course and mechanism of growth hormone's negative feedback effect on its own spontaneous release. Endocrinology, 130: 780-788.
72. Le Roith, D., and Roberts, C.T. (2003) The insulin-like growth factor system and cancer. Cancer Lett., 195: 127-137.
73. Liu, F., Song, Y.K., and Liu, D. (1999) Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther., 6: 1258-1266.
74. Liu, H.W., Ofusu, F.A., and Chang, P.L. (1993) Expression of human factor-IX by microencapsulated recombinant fibroblasts. Hum. Gene Ther., 4: 291-301.
75. Lum, Z., Tai, I.T., Krestow, M., Norton, J., Vacek, I., and Sun, A.M. (1991) Prolonged reversal of diabetic state in NOD mice by xenografts of microencapsulated rat islets. Diabetes, 40: 1511-1515.
76. Mac Leod, J.N., Pampori, N.A., and Shapiro, B.H. (1991) Sex differences in the ultradian pattern of plasma growth hormone concentration in mice. J. Endocrinol., 131: 395-399.
77. Marmary, Y., Parlow, A.F., Goldsmith, C.M., He, X., Wellner, R.B., Satomura, K., Kriete, M.F., Robey, P.G., Nieman, L.K., and Baum, B.J. (1999) Construction and in vivo efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. Endocrinology, 140: 260-265.
78. Mathor, M.B., Ferrari, G., Dellambra, E., Cilli, M., Mavilio, F., Cancedda, R., and De Luca, M. (1996) Clonal analysis of stably transduced human epidermal stem cells in culture. Proc. Natl. Acad. Sci. USA, 93: 10371-10376.
79. Meldrum, D.R., Chang, R.J., Lu, J., Vale, W., Rivier, J., and Judd, H.L. (1982) Medical oophorectomy using a long-acting Gn-RH agonist: a possible new approach to the treatment of endometriosis. J. Clin. Endocrinol. Metab., 54: 1081-1083.
80. Miao, C.H., Thompson, A.R., Loeb, K., and Ye, X. (2001) Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol. Ther., 3: 947-957.
81. Morgan, J.R., Barrandon, Y., Green, H., and Mulligan, R.C. (1987) Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science, 237: 1476-1479.
82. Morgan, R.A., and Anderson W.F. (1993) Human gene therapy. Annu. Rev. Biochem., 62: 191-217.
83. Mulligan, R.C. (1993) The basic science of gene therapy. Science, 260: 926-932.
84. Murphy, J.E., and Rheinwald, J.G. (1997) Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum. Gene Ther., 8: 1867-1879.
85. Nagy, J.A., Shockley, T.R., Masse, E.M., Harvey, V.S., Hoff, C.M., and Jackman, R.W. (1995) Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther., 2: 402-410.
86. Nathwani, A.C., Davidoff, A.M., and Linch, D.C. (2004) A review of gene therapy for haematological disorders. B. J. Haematol., 128: 3-17.
87. O'Connor, N.E,, Mulliken, J.B., Banks-Schlegel, S., Kehinde, O., and Green, H. (1981) Grafting of burns with cultured epithelium prepared from autologous epidermal cells. Lancet, 1: 75-78.
88. Ogilvy-Stuart, A.L., and Gleeson, H. (2004) Cancer risk following growth hormone use in childhood - implications for current practice. Drug Saf., 27: 369-382.
89. Parenteau, N., Sabolinski, M., Prosky, S., Nolte, C., Oleson, M., Kriwet, K, and Bilbo, P. (1996) Biological and physical factors influencing the successful engraftment of a cultured human skin substitute. Biotechnol. Bioeng., 52: 3-14.
90. Pellegrim, G., Bondanza, S., Guerra, L., and De Luca, M. (1998) Cultivation of human keratinocyte stem cells: current and future clinical applications. Med. Biol. Eng. Comput., 36: 778-790.
91. Pellegrini, G., Dellambra, E., Golisano, O., Martinelli, E., Fantozzi, I., Bondanza, S., Ponzin, D., McKeon, F., and De Luca, M. (2001) p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. USA, 98: 3156-3161.
92. Pfutzner, W., and Vogel, J.C. (2000) Advances in skin gene therapy. Exp. Opin. Invest. Drugs, 9: 2069-2083.
93. Pfutzner, W., and Vogel, J.C. (2004) Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo. Cells Tissues Organs, 177: 151-159.
94. Pollack, M.N., Blouin, M.J., Zhang, J.C., and Kopchick, J.J. (2001) Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br. J. Cancer, 85: 428-430.
95. Pollack, M.N., Schernhammer, E.S., and Hankinson, S.E. (2004) Insulin-like growth factors and neoplasia. Nat. Rev. Cancer, 4: 505-518.
96. Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G.P., Wilson, J.M., and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab., 80: 148-158.
97. Rheinwald, J.G., and Green, H. (1975) Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma. Cell, 6: 317-330.
98. Rheinwald, J.G., and Beckett, M.A. (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res., 41: 1657-1663.
99. Rivera, V.M., Clackson, T., Natesan, S., Pollock, R., Amara, J.F., Keenan, T., Magari, S.R., Phillips, T., Courage, N.L., Cerasoli, F. Jr., Holt, D.A., and Gilman, M. (1996) A humanized system for pharmacologic control of gene therapy. Nat. Med., 2: 1028-1032.
100. Rivera, V.M., Ye, X., Courage, N.L., Sachar, J, Cerasoli, Jr. F., Wilson, J.M., and Gilman, M. (1999) Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl. Acad. Sci. USA, 96: 8657-8662.
101. Rosenberg, S.A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R.A., Moen, R., Karson, E.M., Lotze, M.T., Yang, J.C., Topalian, S.L., Merino, M.J., Culver, K., Miller, A.D., Blaese, R.M., and Anderson, W.F. (1990) Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323: 570-578.
102. Ross, C.J.D., Ralph, M., and Chang, P.L. (1999) Delivery of recombinant gene products to the central nervous system with nonautologous cells in alginate microcapsules. Hum. Gene Ther., 10: 49-59.
103. Roth, D.A., Tawa, N.E., O'Brien, J.M., Treco, D.A., and Selden, R.F. (2001) Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N. Engl. J. Med., 344: 1735-1742.
104. Selden, R.F., Skoskiewicz, M.J., Howie, K.B., Russell, P.S., and Goodman, H.M. (1987) Implantation of genetically engineered fibroblasts in mice: implications for gene therapy. Science, 236: 714-718.
105. Selden, R.F., Wagner, T.E., Blethen, S., Yuri, J.S., Rowe, M.E., and Goodman, H.M. (1988) Expression of the human growth hormone variant gene in cultured fibroblasts and transgenic mice. Proc. Natl. Acad. Sci. USA, 85: 8241-8245.
106. Shi, R.H., Yu, H., McLarty, J., and Glass, J. (2004) IGF-I and breast cancer: a meta-analysis. Internat. J. Cancer, 111: 418-423.
107. Sieminski, A.L, Padera, R.F., Blunk, T., and Gooch, K.J. (2002) Systemic delivery of human growth hormone using genetically modified tissue-engineered microvascular networks: prolonged delivery and endothelial survival with inclusion of nonendothelial cells. Tissue Eng., 8: 1057-1069.
108. Sklar, C.A. (2004) Growth hormone treatment: cancer risk. Horm. Res., 62: 30-34.
109. Snibson, K.J., Bhatal, P.S., Hardy, C.L., Brandon, M.R., and Adams, T.E. (1999) High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver, 19: 242-252.
110. Snibson, K.J., Bhatal, P.S., and Adams, T.E. (2001) Overexpressed growth hormone (GH) synergistically promotes carcinogen initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH transgenic mice. Liver, 21: 149-158.
111. Snibson, K.J. (2002) Hepatocellular kinetics and the expression of growth hormone (GH) in the livers and liver tumours of GH-transgenic mice. Tissue Cell, 34: 88-97.
112. Sondergaard, M., Dagnaes-Hansen, F., Flyvbjerg, A., and Jensen, T.G. (2003) Normalization of growth in hypophysectomized mice using hydrodynamic transfer of the human growth hormone gene. Am. J. Physiol. Endocrinol. Metab., 285: E427-E432.
113. Spirito, F., Meneguzzi, G., Danos, O., and Mezzina, M. (2001) Cutaneous gene transfer and therapy: the present and the future. J. Gene Med., 3: 21-31.
114. St George, J.A. (2003) Gene therapy progress and prospects: adenoviral vectors. Gene Ther., 10: 1135-1141.
115. Sun, A.M. (1988) Microencapsulation of pancreatic islet cells: a bioartificial endocrine pancreas. Methods Enzymol., 137: 575-579.
116. Tai, I.T., and Sun, A.M. (1993) Microencapsulation of recombinant cells: a new delivery system for gene therapy. FASEB J., 7: 1061-1069.
117. Taichman, L.B. (1999) Systemic replacement therapy from genetically modified epidermal keratinocytes. Proc. Assoc. Am. Physicians, 111: 206-210.
118. Teumer, J., Lindahl, A., and Green, H. (1990) Human growth hormone in the blood of athymic mice grafted with cultures of hormone-secreting human keratinocytes. FASEB J., 4: 3245-3250.
119. Tomanin, R., and Scarpa, M. (2004) Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr. Gene Ther., 4: 357-372.
120. Tornell, J., Rymo, L., and Isaksson, O.G.P. (1991) Induction of mammary adenocarcinomas in metallothionein promoter human growth-hormone transgenic mice. Internat. J. Cancer, 49: 114-117.
121. Tornell, J., Carlsson, B., Polijanen, P., Wennbo, H., Rymo, L., and Isaksson, O.G.P. (1992) High-frequency of mammary adenocarcinomas in metallothionein promoter human growth-hormone transgenic mice created from 2 different strains of mice. J. Steroid Biochem. Mol. Biol., 43: 237-242.
122. Treco, D.A., and Selden, R.F. (1995) Nonviral gene-therapy. Mol. Med. Today, 1: 314-321.
123. Vandenburgh, H.H., Tatto Del, M., Shansky, J., Lemaire, J., Chang, A., Payumo, F., Lee, P., Goodyear, A., and Raven, L. (1996) Tissue engineered skeletal muscle organoids for reversible gene therapy. Hum. Gene Ther., 7: 2195-2200.
124. Vandenburgh, H., Tatto Del, M., Shansky, J., Goldstein, L., Russell, K., Genes, N., Chromiak, J., and Yamada, S. (1998) Attenuation of skeletal muscle wasting with recombinant human growth hormone secreted from a tissue-engineered bioartificial muscle. Hum. Gene Ther., 9: 2555-2564.
125. Vogt, P.M., Thompson, S., Andree, C., Liu, P., Breuing, K., Hatzis, D., Brown, H., Mulligan, R.C., and Eriksson, E. (1994) Genetically modified keratinocytes transplanted to wounds reconstitute the epidermis. Proc. Natl. Acad. Sci. USA, 91: 9307-9311.
126. Wang, J., Voutetakis, A., Zheng, C., and Baum, B.J. (2004) Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer. Gene Ther., 11: 729-733.
127. Wang, M.S., Childs, R.F., and Chang, P.L. (2005) A novel method to enhance the stability of alginate-poly-L-lysine-alginate microcapsules. J. Biomater. Sci. Polym. Ed., 16: 91-113.
128. Wang, X., Zinkel, S., Polonsky, K., and Fuchs, E. (1997) Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy. Proc. Natl. Acad. Sci. USA, 94: 219-226.
129. Watt, F.M. (2000) Epidermal stem cells as targets for gene therapy. Hum. Gene Ther., 11: 2261-2266.
130. Yi, Y., Hahm, S.H., and Lee, K.H. (2005) Retroviral gene therapy: safety issues and possible solutions. Curr. Gene Ther., 5: 25-35.
131. Zhang, G., Budker, V., and Wolff, J.A. (1999) High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther., 10: 1735-1737.
132. Zwiebel, J.A., Freeman, S.M., Kantoff, P.W., Cornetta, K., Ryan, U.S., and Anderson, W.F. (1989) High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. Science, 243: 220-222.